| Targeting SOCS proteins to control JAK-STAT signalling in disease GA Durham, JJL Williams, MT Nasim, TM Palmer Trends in pharmacological sciences 40 (5), 298-308, 2019 | 137 | 2019 |
| Is there a role for prostanoid-mediated inhibition of IL-6 trans-signalling in the management of pulmonary arterial hypertension? GA Durham, TM Palmer Biochemical Society Transactions 47 (4), 1143-1156, 2019 | 11 | 2019 |
| BS5 Jak-mediated IL-6 and PDGF induced alteration of the metabolic homeostasis of human saphenous vein smooth muscle cells of type 2 diabetic and non-diabetic patients O Bolanle, TM Palmer, RG Sturmey, GA Durham, M Loubani Heart 108 (Suppl 1), A145-A146, 2022 | | 2022 |
| Prostanoid inhibition of IL-6 signalling and function in pulmonary arterial endothelial cells G Durham, T Palmer, T Nasim, C Rutherford BRITISH JOURNAL OF PHARMACOLOGY 177 (11), 2579-2580, 2020 | | 2020 |
| Prostanoid-mediated Inhibition of IL-6 Trans-Signalling in Pulmonary Arterial Hypertension: a Role for Suppressor of Cytokine Signalling 3? GA Durham University of Bradford, 2019 | | 2019 |
| PROSTANOID-MEDIATED INHIBITION OF IL-6 TRANS-SIGNALLING IN PULMONARY ARTERIAL HYPERTENSION: A ROLE FOR EPAC-1 MEDIATED INDUCTION OF'SUPPRESSOR OF CYTOKINE SIGNALLING 3'(SOCS3) G Durham, T Nasim, T Palmer BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 121, 71-72, 2017 | | 2017 |
Timothy M. PalmerProfessor of Cardiovascular Biology, Hull York Medical School, University of HullVerified email at hyms.ac.uk
